PainChek Locks in 4,000 UK Licences as Aged Care Providers Prioritise Pain Tech
PainChek secures 4,000 new UK licences as aged care demand accelerates
PainChek (ASX: PCK) has reported strong sales growth during Q3 FY26, securing 4,000 new contracted licences in the UK aged care market. The expansion represents 9% quarter-on-quarter growth and adds $230,000 AUD in annual recurring revenue (ARR) once implemented. Total UK licences and ARR will be confirmed in the upcoming quarterly business update following 31 March 2026.
The announcement demonstrates sustained commercial traction in a key international territory, where facilities are increasingly prioritising pain management solutions over other technology categories such as falls detection.
When big ASX news breaks, our subscribers know first
Why AI pain assessment is gaining priority in aged care
PainChek’s technology uses artificial intelligence to assess pain in people who cannot reliably self-report, including those living with dementia, disability, or infants aged one month to 12 months. The smartphone and tablet application automates the multidimensional pain assessment process whilst reducing assessor subjectivity and unintentional bias.
The company holds regulatory clearance as a medical device across eight jurisdictions: Australia, USA, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom. This regulatory moat positions the technology as a compliance-driven necessity rather than an optional add-on.
Aged care providers are placing greater emphasis on effective pain management relative to other categories, with PainChek being recognised as a priority solution within settings where pain assessment plays a critical role in meeting quality of care and regulatory expectations.
Key differentiators:
- Regulatory clearances held across eight jurisdictions
- Core use case addresses dementia, disability, and infant populations
- AI-powered automation reduces subjectivity in pain assessment
- Combines automated facial action analysis with Numerical Rating Scale (NRS)
Real-world outcomes reinforcing commercial expansion
Facilities utilising PainChek across the UK are increasingly reporting improved pain identification and management, supporting enhanced resident care and operational efficiencies. The company’s expansion is supported by a growing body of evidence demonstrating impact across large-scale deployments, reinforcing its position as a leading solution in the sector.
PainChek has contracts with over 2,000 aged care facilities globally, with more than 18,000,000 digital pain assessments conducted to date. Clinical studies conducted in Australian and UK residential aged care centres have been published in peer-reviewed journals including the Journal of Alzheimer’s Disease and BMC Geriatrics, validating the technology’s reliability for assessing pain in people with moderate-to-severe dementia.
The evidence-backed adoption profile reduces churn risk and supports potential upsell opportunities as facilities expand usage following initial deployment.
| Metric | Figure |
|---|---|
| New UK licences (Q3 FY26) | 4,000 |
| QoQ UK growth | 9% |
| Additional ARR (once implemented) | $230,000 AUD |
| Global contracted facilities | 2,000+ |
| Total digital assessments | 18,000,000+ |
North America and infant product offer additional growth levers
Beyond the UK, PainChek is making positive progress in North America, where early commercial and strategic initiatives continue to advance. Development and early deployment of the PainChek Infants product is progressing well, with the company expecting to provide updates on these initiatives in due course.
These additional verticals offer optionality for investors beyond the core UK aged care business. North America represents a significantly larger addressable market than the UK, whilst the validated infant application extends the technology’s use case into neonatal and paediatric settings.
Growth vectors by development stage:
- UK aged care: current growth driver with 9% QoQ momentum
- North America: early commercial initiatives progressing
- PainChek Infants: development and early deployment underway
The next major ASX story will hit our subscribers first
CEO signals confidence in global demand trajectory
Management has framed the UK momentum as part of broader positioning to capitalise on increasing global demand for digital health solutions in aged care settings, with major market opportunities still ahead.
Philip Daffas, CEO, PainChek
“We remain well positioned to capitalise on increasing global demand for digital health solutions in aged care settings, with major market opportunities in North America and other verticals still ahead of us.”
The statement reflects confidence supported by commercial traction rather than aspirational commentary, with the UK results validating market demand for the technology in a regulatory-cleared environment.
What investors should watch next
The upcoming quarterly business update, expected after 31 March 2026, will provide confirmation of total UK licences and ARR following Q3 FY26 implementation. This represents the next near-term catalyst for investors tracking execution against the company’s commercialisation targets.
Ongoing updates on North America commercial progress and PainChek Infants deployment are expected to follow in due course, providing visibility on how the company scales beyond its current UK aged care base.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements hit the ASX, so you’re always ahead of the curve.